15 completed. 15 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 15 |
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 2 | Completed 2 |
Follow lanreotide: new trials by email Literature Review of lanreotide trials Research Report on lanreotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands IONIS GHR-LRx, Somatostatin Receptor Ligand (SRL) - Acromegaly | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 39 | 2019-07-25 | 2023-03-22 |
| A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula Lanreotide Prefilled Syringe - Pancreatic Leak, Pancreatic Fistula | Phase 2 | Completed | University of Washington | 114 | 2018-02-20 | 2022-06-16 |
| Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors Lanreotide, Pembrolizumab - Gastroenteropancreatic Neuroendocrine Tumors | Phase 1 / Phase 2 | Completed | Duke University | 22 | 2017-07-01 | 2023-06-29 |
| Lanreotide in the Treatment of Small Bowel Motility Disorders Lanreotide - Gastrointestinal Motility Disorder, Intestinal Disease | Phase 2 | Completed | Northwell Health | 12 | 2017-05-11 | 2021-01-15 |
| Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. Lanreotide (Autogel formulation) and Temozolomide - Neuroendocrine Tumours | Phase 2 | Completed | Ipsen | 40 | 2016-07-01 | 2020-10-01 |
| A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors Ramucirumab, Somatostatin Analog - Carcinoid Tumors | Phase 2 | Completed | Dana-Farber Cancer Institute | 43 | 2016-06-14 | 2025-02-19 |
| Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues Lanreotide - Carcinoma, Merkel Cell | Phase 2 | Completed | University Hospital, Grenoble | 35 | 2015-04-01 | 2017-10-18 |
| Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly Lanreotide PRF - Acromegaly | Phase 1 / Phase 2 | Completed | Ipsen | 28 | 2015-03-01 | 2019-04-25 |
| Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients Lanreotide (acetate) - Malignant Intestinal Obstruction | Phase 2 | Completed | University Hospital, Ghent | 40 | 2009-10-01 | 2014-12-05 |
| Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea lanreotide (Autogel formulation) - Diarrhea | Phase 2 / Phase 3 | Completed | Ipsen | 42 | 2009-07-01 | 2019-01-15 |
| SOMATULINE Autogel 90 mg IN DUMPING SYNDROME Lanreotide 90 mg slow release formulation, Placebo - Dumping Syndrome | Phase 2 | Completed | Universitaire Ziekenhuizen KU Leuven | 24 | 2008-04-01 | 2023-01-27 |
| Lanreotide as Treatment of Polycystic Livers Placebo, Lanreotide - Polycystic Liver Disease, Hepatomegaly | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 38 | 2007-10-01 | 2009-02-17 |
| GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma Octreotide-LAR, Lanreotide Autogel, Locoregional treatments - Advanced Hepatocellular Carcinoma | Phase 2 / Phase 3 | Completed | Federico II University | 25 | 2007-04-01 | 2009-08-17 |
| Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours lanreotide (Autogel formulation) - Neuroendocrine Tumours | Phase 2 | Completed | Ipsen | 30 | 2006-05-01 | 2020-11-05 |
| Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly Lanreotide (Autogel formulation) - Acromegaly | Phase 2 / Phase 3 | Completed | Ipsen | 108 | 2000-05-01 | 2019-08-02 |
Acromegaly (3) · Neuroendocrine Tumors (2) · Carcinoid Tumor (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Diarrhea (1) · Dumping Syndrome (1) · Fistula (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Hepatomegaly (1) · Hyperglycemia (1) · Intestinal Diseases (1) · Liver Diseases (1) · Pancreatic Fistula (1) · Polycystic Kidney, Autosomal Dominant (1)
Ipsen (5) · Dana-Farber Cancer Institute (1) · Duke University (1) · Federico II University (1) · Ionis Pharmaceuticals, Inc. (1) · Northwell Health (1) · Radboud University Medical Center (1) · Universitaire Ziekenhuizen KU Leuven (1) · University Hospital, Ghent (1) · University Hospital, Grenoble (1) · University of Washington (1)
United States (6) · Belgium (5) · France (3) · Italy (3) · Netherlands (3) · Czechia (2) · Germany (2) · Hungary (2) · Lithuania (2) · Poland (2) · Russia (2) · Spain (2) · United Kingdom (2) · Hong Kong (1) · Romania (1)
Annamaria Colao, MD, PhD (1) · Frederik Nevens, MD, PhD (1) · HAINAUT-Wierzbicka Ewa (1) · Jennifer A Chan, MD MPH (1)
PMID 10207464, PMID 10517918, PMID 10573522, PMID 10811995, PMID 10984283, PMID 12066229, PMID 12198662, PMID 12540801, PMID 12591191, PMID 12759473, PMID 14762851, PMID 14974910, PMID 15246216, PMID 16953241, PMID 17589893, PMID 19639415, PMID 24053191, PMID 27423779, PMID 34664531, PMID 36044870, PMID 39356039, PMID 39834129, PMID 42791653, PMID 7568806, PMID 7758431, PMID 8213718, PMID 8635123, PMID 8675143, PMID 8709253, PMID 8903411, PMID 8938543, PMID 9438850, PMID 9593409, PMID 9797392, PMID 9934776
2014 (3), 2004 (1), 2008 (1), 2009 (1), 2019 (1)